Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TB-402 after total hip replacement surgery
2010-023383-40Phase 2Completed
- Sponsor
- Oxurion
- Start
- Jan 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vunacizumab in venous thromboembolism (VTE) (3 arms), sponsored by Oxurion. Primary endpoint: Primary efficacy outcome. Started Jan 2011; status: completed.
02
Drugs
vunacizumab
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on 2010-023383-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023383-40.